Abstract Coronavirus disease 2019 (COVID-19) associated coagulopathy is multifactorial
and involves inflammation driven hypercoagulability, endothelial dysfunction, platelet …

Thrombosis within the microvasculature and medium to large vessels is a serious and
common complication among critically ill individuals with coronavirus disease 2019 (COVID …

Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) is associated with thrombotic complications in …

COVID-19 and multisystem inflammatory syndrome in children (MIS-C) have been
associated with a higher incidence of hypercoagulability and thromboembolic events (TEs) …

Objective Coagulation and inflammatory parameters are mildly altered in children with
SARS-CoV-2 (COVID-19) infection, and laboratory evidence of a proinflammatory and …

Background Multiple investigators have described an increased incidence of
thromboembolic events in SARS‐CoV‐2–infected individuals. Data concerning hemostatic …

Critically ill children with SARS-CoV-2-related illnesses are at increased risk of thrombosis.
Thromboprophylaxis should be considered in select patients with COVID-19 or MIS-C …

Introduction Coagulopathy and thrombosis associated with SARS‐CoV‐2 infection are well
defined in hospitalized adults and leads to adverse outcomes. Pediatric studies are limited …

Background Limited data exist about effective regimens for pharmacological
thromboprophylaxis in children with acute coronavirus disease 2019 (COVID‐19) and …

Background Observational studies indicate that children hospitalized with COVID‐19‐
related illness, like adults, are at increased risk for venous thromboembolism (VTE). A …